Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Taysha Gene Therapies, Inc. (Nasdaq: TSHA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases, Taysha uses these filings to report on its financial condition, capital-raising activities and material developments in its TSHA-102 Rett syndrome program.
Here, users can review Form 8-K current reports in which Taysha describes material events such as amendments to its at-the-market Sales Agreement for common stock, public follow-on offerings, and key press releases. Recent 8-K filings have incorporated announcements on FDA Breakthrough Therapy designation for TSHA-102, alignment on the REVEAL pivotal trial protocol and statistical analysis plan, and the company’s regaining of full rights to its lead TSHA-102 program.
Investors can also use this page to locate references to quarterly and annual financial results, which are furnished as exhibits to 8-K filings, and to understand how Taysha is funding BLA-enabling manufacturing, REVEAL and ASPIRE clinical trial activities, and general corporate operations. The filings identify TSHA as a Nasdaq-listed issuer with common stock registered under Section 12(b) of the Exchange Act and outline the structure of its equity offering programs.
Stock Titan enhances these regulatory documents with AI-powered summaries that explain the key points of lengthy filings in clear language. Users can quickly see what each 8-K covers, track changes to capital programs and material agreements, and follow how clinical and regulatory milestones for TSHA-102 are reflected in Taysha’s official SEC record. Real-time updates from EDGAR, along with structured views of exhibits and items, help readers navigate the company’s filing history efficiently.
Taysha Gene Therapies insider plans small stock sale under Rule 144. A person associated with the company filed to sell 697 shares of common stock through Maxim Group LLC on Nasdaq, with an aggregate market value of $3,289.84, against 273,919,373 shares outstanding.
The shares were acquired on 02/03/2026 via a restricted stock unit (RSU) award that vested and settled in stock in exchange for continued employment. During the prior three months, the same seller disposed of 23,533 shares for $111,781.75 and 7,107 shares for $32,763.27.
Taysha Gene Therapies, Inc. insider Kamran Alam has filed a Rule 144 notice to sell 1,655 shares of common stock through broker Maxim Group LLC on or about 02/04/2026, with an aggregate market value of 7,811.6. The company had 273,919,373 common shares outstanding.
The 1,655 shares to be sold were acquired on 02/03/2026 via an RSU award from the issuer, vesting and settling in stock as compensation for continued employment. In the past three months, Alam previously sold 78,968 and 23,849 common shares for gross proceeds of 375,098.00 and 109,943.89, respectively.
Taysha Gene Therapies President and Head of R&D Nagendran Sukumar reported routine share sales tied to tax withholding. On January 23, 2026, he sold 89,132 shares of common stock at a weighted average price of $4.75. On January 26, 2026, he sold an additional 26,918 shares at a weighted average price of $4.61.
According to the disclosure, these transactions were part of a mandatory sell-to-cover arrangement used solely to satisfy income tax liabilities from vesting restricted stock unit awards. After the reported sales, Sukumar beneficially owned 1,317,389 shares of Taysha Gene Therapies common stock directly.
Taysha Gene Therapies, Inc. Chief Executive Officer and director Nolan Sean P. reported routine stock sales tied to tax withholding on vested equity. On January 23, 2026, he sold 136,789 shares of common stock at a weighted average price of $4.75, and on January 26, 2026 he sold an additional 41,312 shares at a weighted average price of $4.61. According to the disclosure, these transactions were executed under a mandatory sell-to-cover arrangement to satisfy income tax liabilities from restricted stock unit vesting.
Following these sales, Nolan directly beneficially owned 2,908,257 shares of Taysha common stock and indirectly beneficially owned 1,535,545 shares held through Nolan Capital, LLC, where he serves as President with shared voting and investment power.
Taysha Gene Therapies, Inc. chief financial officer Kamran Alam reported sales of company common stock tied to tax withholding on vested equity awards. On January 23, 2026, he sold 78,968 shares of common stock at a weighted average price of $4.75 per share. On January 26, 2026, he sold an additional 23,849 shares at a weighted average price of $4.61 per share. A footnote states these transactions were part of a mandatory sell-to-cover arrangement to satisfy income tax liabilities from the vesting of restricted stock unit awards. After these transactions, Alam beneficially owned 1,443,786 shares of Taysha common stock directly.
Taysha Gene Therapies insider plans Rule 144 sale of stock. A holder has filed to sell 168,078 shares of Taysha Gene Therapies common stock through broker Maxim Group LLC on or about 01/23/2026, with an indicated aggregate market value of $855,517.02. The filing notes that 273,919,373 shares of common stock were outstanding, providing context for the size of the planned sale. The shares to be sold were acquired on 01/23/2026 via a restricted stock unit (RSU) award from the issuer, which vested and was settled in stock as compensation for the reporting person’s continued service as an employee.
TSHA insider files notice to sell common stock under Rule 144. A Form 144 was filed for the planned sale of 113,824 shares of TSHA common stock through broker Maxim Group LLC on Nasdaq, with an aggregate market value of $579,364.16. The filing notes 273,919,373 shares of TSHA common stock outstanding. The shares to be sold were acquired on 01/23/2026 via an RSU award from the issuer, vesting and settling in stock in exchange for the reporting person’s continued service.
The filer also reported prior TSHA stock sales in the past three months: 110,125 shares of common stock sold on 11/28/2025 for gross proceeds of $522,774.39, and 200,000 shares sold on 01/12/2026 for gross proceeds of $942,738.11. By signing the notice, the person for whose account the securities are to be sold represents that they do not know any undisclosed material adverse information about the issuer’s operations.
A holder of TSHA common stock has filed a notice of proposed sale under Rule 144. The filing covers 30,052 shares of common stock to be sold through Maxim Group LLC on the Nasdaq, with an aggregate market value of $152,964.68. The filing notes that 273,919,373 shares of this class were outstanding at the time of the notice.
The shares to be sold were acquired on 01/23/2026 as a restricted stock unit (RSU) award from the issuer. The RSUs vested and were settled in stock on that date, with the consideration described as the reporting person’s continued service as an employee of the issuer. The signer also represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Taysha Gene Therapies (TSHA) has a planned sale of 54,916 shares of common stock under a Form 144 notice. The shares are to be sold through Maxim Group LLC on the Nasdaq, with an aggregate market value of 279,522.44 and an approximate sale date of 01/23/2026. The issuer reports 273,919,373 shares of this class outstanding.
The shares come from a restricted stock unit (RSU) award acquired on 01/23/2026, which vested and was settled in stock on the same date. The consideration for the grant was the reporting person’s continued service as an employee of the issuer.
An affiliate of the issuer has filed a notice of proposed sale of 32,077 shares of common stock under Rule 144. The planned sale, with an aggregate market value of $163,271.93, is to be executed through Maxim Group LLC on or about 01/23/2026 on the Nasdaq exchange.
The 32,077 shares were acquired on 01/23/2026 via an RSU award from the issuer, with payment in the form of the reporting person’s continued employment and the award vesting and settling in stock on that date. The filing notes that there were 273,919,373 shares of this class of common stock outstanding.